Dossier
Lantus Solostar
Coverage of Lantus Solostar in the Nexus archive.
- STAT+: Pharmalittle: We’re reading about an FDA panel and peptides, a Merck license for an HIV pill, and more
An FDA advisory panel recommended allowing compounding pharmacies to produce peptides like BPC-157 and TB-500, despite FDA staff concerns about safety and efficacy. Sanofi's long-acting insulin pen, Lantus Solostar, faces supply shortages due to increased demand, causing challenges for diabetes patients.
- STAT+: Popular insulin product enters shortage as other pens leave market
Sanofi's Lantus Solostar insulin pen is experiencing supply issues due to increased demand, causing patients to struggle to find medication. The FDA does not classify the situation as a shortage, but Sanofi is accelerating production to address the problem.